In patients who met the criteria for prasugrel use recommended by the European Medicines Agency , thus excluding from the analysis patients with prior transient ischemic attack ( TIA ) / stroke , with weight < 60 kg or age 75 years , and censoring follow-up at 365 days , ( European Union ( EU ) - label cohort ) prasugrel showed superiority over clopidogrel with regard to the primary endpoint ( HR 0.73 , 95 % CI 0.63-0 .85 , p < 0.0001 ) for the entire NSTE-ACS population , as well as for UA patients and NSTEMI patients without significant differences in non-CABG TIMI major bleeding .